Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05953337 · ClinicalTrials.gov registry record · NA

Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)

A NA study of Hepatocellular Carcinoma and Liver Cancer, sponsored by ABK Biomedical.

Active
Registry status
NA
Development phase
120
Enrollment target
20
Study locations

NCT05953337 is a NA study of Hepatocellular Carcinoma and Liver Cancer that is active but no longer recruiting, run by ABK Biomedical. The registered enrollment target is 120 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05953337, a NA study of Hepatocellular Carcinoma and Liver Cancer, is active but no longer recruiting, sponsored by ABK Biomedical.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provides local radiation brachytherapy for the treatment of liver tumors.

Conditions Studied

Hepatocellular Carcinoma Liver Cancer Hepatocellular Carcinoma Non-resectable

Interventions

  • DEVICE EYE90 Microspheres Treatment

Study Locations (20)

Florida

  • AdventHealth Radiation Oncology at Altamonte Springs - Altamonte Springs
  • Miami Cardiac and Vascular Institute at Baptist Hospital Miami - Miami

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Piedmont Hospital - Atlanta

Illinois

  • Northwestern University Memorial Hospital - Chicago
  • University of Illinois Hospital and Health Sciences System - Chicago

Missouri

  • University of Missouri - Ellis Fischel Cancer Center - Columbia
  • SSM Health Saint Louis University - St Louis

Arizona

  • The University of Arizona Cancer Center - Tucson

California

  • University of California - Irvine - Orange

Iowa

  • University of Iowa Health Care - Iowa City

Kentucky

  • University of Louisville - Louisville

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2023-09-21
Est. Completion 2027-02
Phase NA

Sponsor

ABK Biomedical

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05953337

The ClinicalTrials.gov registry entry for NCT05953337 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (53% lower). The listed sponsor is ABK Biomedical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which EYE90 Microspheres Treatment is the first listed.

NCT05953337 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT05953337 about?

NCT05953337 is a clinical study titled "Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)". This is a prospective, multi-center, open-label study to evaluate the effectiveness and safety of Eye90 microspheres® in the treatment of subjects with unresectable Hepatocellular Carcinoma (HCC). Eye90 microspheres is a medical device containing yttrium-90 (Y-90), a radioactive material, and provid...

What is the current status of trial NCT05953337?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2023-09-21. Estimated completion is 2027-02.

What conditions does trial NCT05953337 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Liver Cancer, Hepatocellular Carcinoma Non-resectable.

What interventions are being tested in trial NCT05953337?

The interventions under investigation include: EYE90 Microspheres Treatment (DEVICE).

Who is sponsoring clinical trial NCT05953337?

This trial is sponsored by ABK Biomedical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05953337 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Liver Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.